Paterson B, Fraser H, Wang C, Marcus R. A Randomized, double-blind, placebo-controlled, sequential parallel study of CERC-301 in the adjunctive treatment of subjects with severe depression and recent active suicidal ideation despite antidepressant treatment. Presented at the 2015 National Network of Depression Centers Annual Conference, November-2015, Ann Arbor, MI, USA
Paterson B, Fraser H, Garner R, Mazhari R, Marcus R. A randomized, double-blind, placebo-controlled, parallel-group, three-part safety, pharmacokinetic, and pharmcodynamic study of CERC-301 in healthy subjects. Presented at the 2015 National Network of Depression Centers Annual Conference, November-2015, Ann Arbor, MI, USA
Ibrahim L, Diaz Granados N, Jolkovsky L, et. al. A Randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder. J Clin Psychopharmacol. 2012 Aug;32(4):551-7. doi: 10.1097/JCP.0b013e31825d70d6. (PMID: 22722512)
Preskorn SH, Baker B, Kolluri S, Menniti FS, Krams M, Landen JW. An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder. J Clin Psychopharmacol. 2008 Dec;28(6):631-7. doi: 10.1097/JCP.0b013e31818a6cea. (PMID: 19011431)
Machado-Vieira R, Salvadore G, Diazgranados N, Zarate CA Jr. Ketamine and the next generation of antidepressants with a rapid onset of action. Pharmacol Ther. 2009 Aug;123(2):143-50. doi: 10.1016/j.pharmthera.2009.02.010. Epub 2009 May 3. (PMID: 19397926)
Duman RS, Aghajanian GK. Synaptic dysfunction in depression: potential therapeutic targets. Science. 2012 Oct 5;338(6103):68-72. doi: 10.1126/science.1222939. (PMID: 23042884)
Disclaimer: These links are being provided as a convenience and for informational purposes only. The views, opinions and conclusions expressed in the links above are those of the authors and do not necessarily reflect the views, opinions and conclusions of the Company. The Company bears no responsibility for the accuracy, legality or content of any external links.